|
|
Post by pguererro on May 22, 2018 8:24:22 GMT -5
Kastanes (thanks for the weekly data) asked what’s the difference between the label change and STAT? Huge difference. We had been talking pkpd for a year prior to label change. It just extra verified what we knew already du to the head to head pkpd analysis vs humalog. Expressing this to prescribers is still a theory of what SHOULD happen if u use Afrezza instead of humalog. Turned out docs weren’t interested in what we thought would be the scenario. The Stat trial is what DID happen when we compared Afrezza to Novolog. Big difference. The type 1 and type 2 studies are far from compelling to a prescriber. With the doc confusion on how to use Afrezza we can now say When you dose like This your patient will respond like This. Head to head trials are impactful.
|
|
|
|
Post by peppy on May 22, 2018 9:38:50 GMT -5
I have a suggestion for MNKD at the ADA.
Have tee-shirts made for MNKD sales staff/staff with the continuous glucose monitor screens shots obtained from the STAT study.
'Afrezza, glucose control STAT'
Thanks pguererro. Nice post.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on May 22, 2018 10:13:45 GMT -5
pguererro - I get that. What I don't get, how will that translate into greater coverage which in my opinion is holding scripts down.
|
|
|
|
Post by lennymnkd on May 22, 2018 10:24:06 GMT -5
pguererro - I get that. What I don't get, how will that translate into greater coverage which in my opinion is holding scripts down. At some point in all this , are insurers not required to comply on medical data that’s effective. |
|
|
|
Post by ilovekauai on May 22, 2018 10:25:11 GMT -5
Kastanes: My memory of last week's ASM is fading off the radar screen, but think that issue was discussed. Wish I could be of further help to your concerns.
|
|
|
|
Post by pguererro on May 22, 2018 10:30:00 GMT -5
Kastanes: You are correct. Managed Care is a major thorn to growth. However so far the demand for Afrezza has not convinced MC to change their stance or stipulations with Afrezza (plus the pricing). This approach Mannkind is taking is to drive demand to the point where with PA’s and Appeal letters “push” Afrezza through and “sting” the MC companies with $$ and time spent on dealing with reimbursement of Afrezza. This will loosen up the stipulations. STAT hopefully drives demand. Time will tell if this approach works, but this will be the best tool we’ve had to truly drive scripts (for Type 1).
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on May 22, 2018 10:53:47 GMT -5
pguererro "Time will tell if this approach works" MannKind doesn't have the cash to reset if that approach doesn't work. I know longs don't want to hear that but the reality is Afrezza revenue willnot keep the lights on. Something has to give soon.
|
|
|
|
Post by pguererro on May 22, 2018 10:56:07 GMT -5
Kastanes: I could not agree more with that statement.
|
|
|
|
Post by traderdennis on May 22, 2018 12:06:26 GMT -5
Kastanes: You are correct. Managed Care is a major thorn to growth. However so far the demand for Afrezza has not convinced MC to change their stance or stipulations with Afrezza (plus the pricing). This approach Mannkind is taking is to drive demand to the point where with PA’s and Appeal letters “push” Afrezza through and “sting” the MC companies with $$ and time spent on dealing with reimbursement of Afrezza. This will loosen up the stipulations. STAT hopefully drives demand. Time will tell if this approach works, but this will be the best tool we’ve had to truly drive scripts (for Type 1). It is possible ADA could push through a new standard of care which the managed care would start to cover. I doubt it would happen at this ADA |
|
|
|
Post by lakers on May 22, 2018 12:21:10 GMT -5
Kastanes: I could not agree more with that statement. PG, since you are an employee and an evangelist, what’s your proposed solution? Think out of the box. |
|
|
|
Post by pguererro on May 22, 2018 12:59:07 GMT -5
Evangelist? Start living in reality.
|
|
|
|
Post by pguererro on May 22, 2018 13:00:56 GMT -5
Lakers: we’re on the same team here. I think I just told you what “the plan/solution is...read above. No reason for name calling
|
|
|
|
Post by goyocafe on May 22, 2018 13:15:00 GMT -5
Kastanes: You are correct. Managed Care is a major thorn to growth. However so far the demand for Afrezza has not convinced MC to change their stance or stipulations with Afrezza (plus the pricing). This approach Mannkind is taking is to drive demand to the point where with PA’s and Appeal letters “push” Afrezza through and “sting” the MC companies with $$ and time spent on dealing with reimbursement of Afrezza. This will loosen up the stipulations. STAT hopefully drives demand. Time will tell if this approach works, but this will be the best tool we’ve had to truly drive scripts (for Type 1). And here I thought approval was going to be the hardest part. Who knew?!  |
|
|
|
Post by lakers on May 22, 2018 13:25:27 GMT -5
PG. Don’t get me wrong. You are well respected. Your idea counts. Solution toward mkt access, cash crunch that has not been thought about. Still waiting for NEJM, Lancet, AJMA.
|
|
|
|
Post by mnholdem on May 22, 2018 14:11:13 GMT -5
Evangelist? Start living in reality. That's what all evangelists say. ;-) |
|
